Multimodal imaging analysis of an orthotopic head and neck cancer mouse model and application of anti-CD137 tumor immune therapy
Corresponding Author
Anne-Kristin Vahle MD
Department of Otorhinolaryngology, University Hospital Essen, Essen, Germany
Corresponding author: A.-K. Vahle, Department of Otorhinolaryngology, University Hospital Essen, Hufelandstr. 55, 45122 Essen, Germany. E-mail: [email protected]Search for more papers by this authorSven Hermann MD
European Institute for Molecular Imaging, University of Münster, Münster, Germany
Search for more papers by this authorMichael Schäfers MD
European Institute for Molecular Imaging, University of Münster, Münster, Germany
Department of Nuclear Medicine, University Hospital Münster, Germany
Cluster of Excellence EXC 1003 “CiM – Cells in Motion,”, University of Münster, Münster, Germany
Search for more papers by this authorMichael Wildner
Department of Otorhinolaryngology, University Hospital Essen, Essen, Germany
Search for more papers by this authorAlexander Kerem MD
Department of Otorhinolaryngology, University Hospital Essen, Essen, Germany
Search for more papers by this authorEnder Öztürk MD
Department of Otorhinolaryngology, University Hospital Essen, Essen, Germany
Search for more papers by this authorMaria Jure–Kunkel PhD
Bristol–Myers Squibb Company, New York, New York
Search for more papers by this authorCindy Franklin MD
Department of Otorhinolaryngology, University Hospital Essen, Essen, Germany
Search for more papers by this authorStephan Lang MD
Department of Otorhinolaryngology, University Hospital Essen, Essen, Germany
Search for more papers by this authorSven Brandau PhD
Department of Otorhinolaryngology, University Hospital Essen, Essen, Germany
Search for more papers by this authorCorresponding Author
Anne-Kristin Vahle MD
Department of Otorhinolaryngology, University Hospital Essen, Essen, Germany
Corresponding author: A.-K. Vahle, Department of Otorhinolaryngology, University Hospital Essen, Hufelandstr. 55, 45122 Essen, Germany. E-mail: [email protected]Search for more papers by this authorSven Hermann MD
European Institute for Molecular Imaging, University of Münster, Münster, Germany
Search for more papers by this authorMichael Schäfers MD
European Institute for Molecular Imaging, University of Münster, Münster, Germany
Department of Nuclear Medicine, University Hospital Münster, Germany
Cluster of Excellence EXC 1003 “CiM – Cells in Motion,”, University of Münster, Münster, Germany
Search for more papers by this authorMichael Wildner
Department of Otorhinolaryngology, University Hospital Essen, Essen, Germany
Search for more papers by this authorAlexander Kerem MD
Department of Otorhinolaryngology, University Hospital Essen, Essen, Germany
Search for more papers by this authorEnder Öztürk MD
Department of Otorhinolaryngology, University Hospital Essen, Essen, Germany
Search for more papers by this authorMaria Jure–Kunkel PhD
Bristol–Myers Squibb Company, New York, New York
Search for more papers by this authorCindy Franklin MD
Department of Otorhinolaryngology, University Hospital Essen, Essen, Germany
Search for more papers by this authorStephan Lang MD
Department of Otorhinolaryngology, University Hospital Essen, Essen, Germany
Search for more papers by this authorSven Brandau PhD
Department of Otorhinolaryngology, University Hospital Essen, Essen, Germany
Search for more papers by this authorConflict of interest: Maria Jure-Kunkel is an employee at Bristol Myers Squibb. Bristol Myers Squibb owns stock of anti-CD137 antibody. All other authors have no conflict of interests.
Abstract
Background
Recent technical progress makes sophisticated noninvasive imaging methods available for murine models. For the first time, in this study, we applied fluorodeoxyglucose (FDG)-positron emission tomography (PET)-CT and FDG-PET-MRI to a murine orthotopic model of head and neck cancer immunotherapy.
Methods
Tumor growth of floor of the mouth tumors was evaluated by multimodal small-animal imaging using FDG-PET-CT and FDG-PET-MRI. The immunotherapeutic effects of anti-CD137 antibody therapy were examined on body weight, tumor growth, and tumor-infiltrating immune cells in longitudinal imaging studies and immunohistochemical analyses.
Results
Imaging revealed aggressive, fast-growing tumors without evidence of local or distant metastases. CD137 immunotherapy decreased tumor take and growth and stabilized body weight over time. A clear case of tumor regression was demonstrated by longitudinal PET-CT.
Conclusion
The murine model mimics the characteristics of head and neck cancer in humans and offers excellent opportunities to investigate immunomodulatory anticancer drugs. The CD137 antibody showed antitumor effects in some therapy-responsive mice. © 2015 Wiley Periodicals, Inc. Head Neck 38: 542–549, 2016
REFERENCES
- 1 Vahle AK, Kerem A, Oztürk E, Bankfalvi A, Lang S, Brandau S. Optimization of an orthotopic murine model of head and neck squamous cell carcinoma in fully immunocompetent mice–role of toll-like-receptor 4 expressed on host cells. Cancer Lett 2012; 317: 199–206.
- 2 O'Malley BW Jr, Cope KA, Johnson CS, Schwartz MR. A new immunocompetent murine model for oral cancer. Arch Otolaryngol Head Neck Surg 1997; 123: 20–24.
- 3 Sun R, Zhang JG, Guo CB. Establishment of cervical lymph node metastasis model of squamous cell carcinoma in the oral cavity in mice. Chin Med J (Engl) 2008; 121: 1891–1895.
- 4 Bussink J, Kaanders JH, van der Graaf WT, Oyen WJ. PET-CT for radiotherapy treatment planning and response monitoring in solid tumors. Nat Rev Clin Oncol 2011; 8: 233–242.
- 5 Garsa AA, Chang AJ, Dewees T, et al. Prognostic value of F-FDG PET metabolic parameters in oropharyngeal squamous cell carcinoma. J Radiat Oncol 2013; 2: 27–34.
- 6 Franzius C, Hotfilder M, Poremba C, et al. Successful high-resolution animal positron emission tomography of human Ewing tumours and their metastases in a murine xenograft model. Eur J Nucl Med Mol Imaging 2006; 33: 1432–1441.
- 7 Hoeben BA, Starmans MH, Leijenaar RT, et al. Systematic analysis of 18F-FDG PET and metabolism, proliferation and hypoxia markers for classification of head and neck tumors. BMC Cancer 2014; 14: 130.
- 8 Schäfers KP, Reader AJ, Kriens M, Knoess C, Schober O, Schäfers M. Performance evaluation of the 32-module quadHIDAC small-animal PET scanner. J Nucl Med 2005; 46: 996–1004.
- 9 Riemann B, Schäfers KP, Schober O, Schäfers M. Small animal PET in preclinical studies: opportunities and challenges. Q J Nucl Med Mol Imaging 2008; 52: 215–221.
- 10 Doré–Savard L, Barrière DA, Midavaine É, et al. Mammary cancer bone metastasis follow-up using multimodal small-animal MR and PET imaging. J Nucl Med 2013; 54: 944–952.
- 11 Adappa ND, Sung CK, Choi B, Huang TG, Genden EM, Shin EJ. The administration of IL-12/GM-CSF and Ig-4-1BB ligand markedly decreases murine floor of mouth squamous cell cancer. Otolaryngol Head Neck Surg 2008; 139: 442–448.
- 12 Cheuk AT, Mufti GJ, Guinn BA. Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Ther 2004; 11: 215–226.
- 13 Lynch DH. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer. Immunol Rev 2008; 222: 277–286.
- 14 Miller RE, Jones J, Le T, et al. 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J Immunol 2002; 169: 1792–1800.
- 15 Ascierto PA, Simeone E, Sznol M, Fu YX, Melero I. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 2010; 37: 508–516.
- 16 Melero I, Murillo O, Dubrot J, Hervás–Stubbs S, Perez–Gracia JL. Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies. Trends Pharmacol Sci 2008; 29: 383–390.
- 17 Xu D, Gu P, Pan PY, Li Q, Sato AI, Chen SH. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int J Cancer 2004; 109: 499–506.
- 18 Xu DP, Sauter BV, Huang TG, Meseck M, Woo SL, Chen SH. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma. Gene Ther 2005; 12: 1526–1533.
- 19 Pan PY, Gu P, Li Q, Xu D, Weber K, Chen SH. Regulation of dendritic cell function by NK cells: mechanisms underlying the synergism in the combination therapy of IL-12 and 4-1BB activation. J Immunol 2004; 172: 4779–4789.
- 20 Melero I, Shuford WW, Newby SA, et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997; 3: 682–685.
- 21 Myers L, Lee SW, Rossi RJ, et al. Combined CD137 (4-1BB) and adjuvant therapy generates a developing pool of peptide-specific CD8 memory T cells. Int Immunol 2006; 18: 325–333.
- 22 Vinay DS, Kwon BS. Immunotherapy of cancer with 4-1BB. Mol Cancer Ther 2012; 11: 1062–1070.
- 23 Baruah P, Lee M, Odutoye T, et al. Decreased levels of alternative co-stimulatory receptors OX40 and 4-1BB characterise T cells from head and neck cancer patients. Immunobiology 2012; 217: 669–675.
- 24 Albers AE, Strauss L, Liao T, Hoffmann TK, Kaufmann AM. T cell-tumor interaction directs the development of immunotherapies in head and neck cancer. Clin Dev Immunol 2010; 2010: 236378.
- 25 Schäfers KP, Reader AJ, Kriens M, Knoess C, Schober O, Schäfers M. Performance evaluation of the 32-module quadHIDAC small-animal PET scanner. J Nucl Med 2005; 46: 996–1004.
- 26 Joo YH, Yoo IR, Cho KJ, Park JO, Nam IC, Kim MS. Extracapsular spread in hypopharyngeal squamous cell carcinoma: diagnostic value of FDG PET/CT. Head Neck 2013; 35: 1771–1776.
- 27 Dibble EH, Alvarez AC, Truong MT, Mercier G, Cook EF, Subramaniam RM. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. J Nucl Med 2012; 53: 709–715.
- 28 Abgral R, Le Roux PY, Rousset J, et al. Prognostic value of dual-time-point 18F-FDG PET-CT imaging in patients with head and neck squamous cell carcinoma. Nucl Med Commun 2013; 34: 551–556.
- 29 Pantaleo MA, Mishani E, Nanni C, et al. Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET. Mol Imaging Biol 2010; 12: 616–625.
- 30 Saindane AM. Pitfalls in the staging of cervical lymph node metastasis. Neuroimaging Clin N Am 2013; 23: 147–166.
- 31 Petruzzi N, Shanthly N, Thakur M. Recent trends in soft-tissue infection imaging. Semin Nucl Med 2009; 39: 115–123.
- 32 Al-Nabhani K, Syed R, Haroon A, Almukhailed O, Bomanji J. Flare response versus disease progression in patients with non-small cell lung cancer. J Radiol Case Rep 2012; 6: 34–42.
- 33 Koba W, Jelicks LA, Fine EJ. MicroPET/SPECT/CT imaging of small animal models of disease. Am J Pathol 2013; 182: 319–324.
- 34 Chen AY, Hudgins PA. Pitfalls in the staging squamous cell carcinoma of the hypopharynx. Neuroimaging Clin N Am 2013; 23: 67–79.
- 35 Herzog H. PET/MRI: challenges, solutions and perspectives. Z Med Phys 2012; 22: 281–298.
- 36 Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009; 9: 271–285.
- 37 Elpek KG, Yolcu ES, Franke DD, Lacelle C, Schabowsky RH, Shirwan H. Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling. J Immunol 2007; 179: 7295–7304.
Citing Literature
